History of meningococcal vaccines and their serological correlates of protection

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Vipond, Caroline ^a   Care, Rory ^a   Feavers, Ian M ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Bactericidal antibody; Complement; Gene expression; Meningitis; Outer membrane vesicle; Polysaccharide; Serological correlate; Vaccine

Indexed keywords

GLYCOCONJUGATE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE;

ARTICLE; CROSS PROTECTION; HUMAN; IMMUNOGENICITY; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; VACCINATION;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 84861169835     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.060     Document Type: Article

References (125)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N Engl J Med 2001, 344(18):1378-1388.
2. Maiden M.C.J., Caugant D.A. The population biology of Neisseria meningitidis: implications for meningococcal disease, epidemiology and control. Handbook of Meningococcal Disease 2006, 17-35. Wiley-VCH, Weinheim. M. Frosch, M.C.J. Maiden (Eds.).
3. Peltola H. Meningococcal disease: still with us. Rev Infect Dis 1983, 5(1):71-91.
4. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983, 2(3846):355-357.
5. Underwood E.A. Recent knowledge of the incidence and control of cerebrospinal fever. Br Med J 1940, 1(4140):757-763.
6. Greenwood M. The outbreak of cerebrospinal fever at salisbury in 1914-15. Proc R Soc Med 1917; 10(Sect Epidemiol State Med): 44-60.
7. Riding D., Corkill N.L. Prophylactic vaccination in epidemic meningococcal meningitis. J Hyg (Lond) 1932, 32(2):258-267.
8. Finland M., Ruegsegger J.M. Immunization of human subjects with specific carbohydrates of Type III and the related Type VIII pneumococcus. J Clin Invest 1935, 14(6):829-832.
9. Finland M., Dowling H.F. Cutaneous reactions and antibody response to intracutaneous injections of pneumococcus polysaccharides. J Immunol 1935, 29(4):285-299.
10. Francis T., Tillett W.S. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J Exp Med 1930, 52(4):573-585.
11. Kabat E.A., Kaiser H., Sikorski H. Preparation of the type specific polysaccharide of the type I meningococcus and a study of its effectiveness as an antigen in human beings. J Exp Med 1944, 80(4):229-307.
12. Scherp H.W., Rake G. Studies on meningococcus infection: viii. The type i specific substance. J Exp Med 1935, 61(6):753-769.
13. Kabat E.A., Bezer A.E. The effect of variation on molecular weight on the antigenicity of dextran in man. Arch Biochem 1958, 78(2):306-313.
14. Gotschlich E.C., Liu T.Y., Artenstein M.S. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 1969, 129(6):1349-1365.
15. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus IV. Immunogenicity of group A and group C meningococcal polysaccharides. J Exp Med 1969, 129(6):1367-1384.
16. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970, 282(8):417-420.
17. Artenstein M.S. Control of meningococcal meningitis with meningococcal vaccines. Yale J Biol Med 1975, 48(3):197-200.
18. Gold R., Artenstein M.S. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Org 1971, 45(3):279-282.
19. Wahdan M.H., Sallam S.A., Hassan M.N., Abdel G.A., Rakha A.S., Sippel J.E., et al. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Org 1977, 55(6):645-651.
20. Wahdan M.H., Rizk F., El Akkad A.M., El Ghoroury A.A., Hablas R., Girgis N.I., et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Org 1973, 48(6):667-673.
21. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
22. Gold R., Lepow M.L., Goldschneider I., Draper T.L., Gotschlich E.C. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975, 56(6):1536-1547.
23. Peltola H., Makela H., Kayhty H., Jousimies H., Herva E., Hallstrom K., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977, 297(13):686-691.
24. Maslanka S.E., Tappero J.W., Plikaytis B.D., Brumberg R.S., Dykes J.K., Gheesling L.L., et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998, 66(6):2453-2459.
25. Granoff D.M., Gupta R.K., Belshe R.B., Anderson E.L. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998, 178(3):870-874.
26. Jokhdar H., Borrow R., Sultan A., Adi M., Riley C., Fuller E., et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004, 11(1):83-88.
27. Moxon E.R., Heath P.T., Booy R., Azzopardi H.J., Slack M.P., Ramsay M.E. 4th European conference on vaccinology: societal value of vaccination. The impact of Hib conjugate vaccines in preventing invasive H. influenzae diseases in the UK. Vaccine 1999, 17(Suppl. 3):S11-S13.
28. Eskola J., Takala A.K., Kayhty H. Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children. Curr Opin Pediatr 1993, 5(1):55-59.
29. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993, 269(2):221-226.
30. Borrow R., Andrews N., Findlow H., Waight P., Southern J., Crowley-Luke A., et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010, 17(1):154-159.
31. Southern J., Borrow R., Andrews N., Morris R., Waight P., Hudson M., et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009, 16(2):194-199.
32. Ramsay M., Kaczmarski E., Rush M., Mallard R., Farrington P., White J. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997, 7(4):R49-R54.
33. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Suppl. 1):S58-S67.
34. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002, 51(9):717-722.
35. Campbell H., Borrow R., Salisbury D., Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009, 27(Suppl. 2):B20-B29.
36. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., van der Ende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006, 25(1):79-80.
37. Cano R., Larrauri A., Mateo S., Alcala B., Salcedo C., Vazquez J.A. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 2004, 9(7):11-15.
38. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009, 28(3):220-224.
39. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364(9431):365-367.
40. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69(3):1568-1573.
41. Siber G.R. Methods for estimating serological correlates of protection. Dev Biol Stand 1997, 89:283-296.
42. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10(5):780-786.
43. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999, 179(6):1569-1572.
44. Richmond P., Borrow R., Goldblatt D., Findlow J., Martin S., Morris R., et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001, 183(1):160-163.
45. Maiden M.C., Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359(9320):1829-1831.
46. Maiden M.C., Ibarz-Pavon A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197(5):737-743.
47. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326(7385):365-366.
48. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364(24):2293-2304.
49. Yogev R, Tan T. Meningococcal disease: The advances and challenges of meningococcal disease prevention. Hum Vaccin 2011; 7(8)epub.
50. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972, 126(5):514-522.
51. Frasch C.E., Peppler M.S. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun 1982, 37(1):271-280.
52. Frasch C.E., Parkes L., McNelis R.M., Gotschlich E.C. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model. J Exp Med 1976, 144(2):319-329.
53. Moreno C., Lifely M.R., Esdaile J. Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide. Infect Immun 1985, 47(2):527-533.
54. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein in man. J Clin Invest 1979, 63(5):836-848.
55. Froholm L.O., Berdal B.P., Bovre K., Gaustad P., Harboe A., Holten E., et al. Meningococcal group B vaccine trial in Norway 1981-1982. Preliminary report of results available November 1982. NIPH Ann 1983, 6(2):133-138.
56. Finne J. Polysialic acid - a glycoprotein carbohydrate involved in neural adhesion and bacterial meningitis. TIBS 1985, 129-132.
57. Frasch C.E., Chapman S. Classification of Neisseria meningitidis Group B into distinct serotypes I. serological typing by a microbacterial method. Infect Immun 1972, 5(1):98-102.
58. Winkelhake J.L., Kasper D.L. Affinity chromatography of anti-meningococcal antiserum. J Immunol 1972, 109(4):824-833.
59. Frasch C.E., Gotschlich E.C. An outer membrane protein of Neisseria meningitidis group B responsible for serotype specificity. J Exp Med 1974, 140(1):87-104.
60. Zollinger W.D., Mandrell R.E., Altieri P., Berman S., Lowenthal J., Artenstein M.S. Safety and immunogenicity of a Neisseria meningitidis Type 2 protein vaccine in animals and humans. J Infect Dis 1978, 137(6):728-739.
61. Mandrell R.E., Zollinger W.D. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect Immun 1989, 57(5):1590-1598.
62. Saukkonen K., Abdillahi H., Poolman J.T., Leinonen M. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B: 15: P1. 16 in infant rat infection model; new prospects for vaccine development. Microb Pathogen 1987, 3(4):261-267.
63. Saukkonen K., Leinonen M., Abdillahi H., Poolman J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 1989, 7(4):325-328.
64. Devoe I.W., Gilchrist J.E. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 1973, 138(5):1156-1167.
65. Poolman J.T., van der Ley P.A., Wiertz E.J., Hoogerhout P. Second generation meningococcal OMP-LPS vaccines. NIPH Ann 1991, 14(2):233-241.
66. Frasch C.E., Mocca L.F., Karpas A.B. Appearance of new strains associated with group B meningococcal disease and their use for rapid vaccine development. Antonie van Leeuwenhoek 1987, 53(6):395-402.
67. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14(2):195-207.
68. Padron F.S., Huergo C.C., Gil V.C., Diaz E.M.F., Valdespino I.E.C., Gotera N.G. Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application. MEDICC Review 2007, 9(1):16-21.
69. Reed G., Galindo M.A. Cuba's national immunization program. MEDICC Rev 2007, 9(1):5-7.
70. de Moraes J.C., Perkins B.A., Camargo M.C., Hidalgo N.T., Barbosa H.A., Sacchi C.T., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992, 340(8827):1074-1078.
71. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1. 3) outer membrane protein vaccine in Iquique, Chile. Chilean national committee for meningococcal disease. Vaccine 1995, 13(9):821-829.
72. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Froholm L.O., et al. Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991, 14(2):67-79.
73. Holst J., Feiring B., Fuglesang J.E., Hoiby E.A., Nokleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21(7-8):734-737.
74. Feiring B., Fuglesang J., Oster P., Naess L.M., Helland O.S., Tilman S., et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 2006, 13(7):790-796.
75. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995, 63(12):4642-4652.
76. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998, 177(3):683-691.
77. Naess L.M., Aarvak T., Aase A., Oftung F., Hoiby E.A., Sandin R., et al. Human IgG subclass responses in realtion to serum bactericidal and opsonic activities after immunisation with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 1999, 17(7-8):754-764.
78. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281(16):1520-1527.
79. Sexton K., Lennon D., Oster P., Crengle S., Martin D., Mulholland K., et al. The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J 2004, 117(1200):U1015.
80. Sexton K., Lennon D., Oster P., Aaberge I., Martin D., Reid S., et al. Proceedings of the Meningococcal Vaccine Strategy World Health Organization Satellite Meeting. N Z Med J 2004, 117(1200):1.
81. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(17-18):2191-2196.
82. Oster P., O'Hallahan J., Aaberge I., Tilman S., Ypma E., Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007, 25(16):3075-3079.
83. Jackson C., Lennon D., Wong S., Yan J., Stewart J., Reid S., et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child 2011, 96(8):744-751.
84. Galloway Y., Stehr-Green P., McNicholas A., O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009, 38(2):413-418.
85. Loring B.J., Turner N., Petousis-Harris H. MeNZB(TM) vaccine and epidemic control: when do you stop vaccinating?. Vaccine 2008, 26(47):5899-5904.
86. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H., et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994, 62(10):4419-4424.
87. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166(7):817-823.
88. Milagres L.G., Gorla M.C.A., Sacchi C.T., Rodrigues M.M. Specificity of bactericidal antibody response to serogroup B meningococcal strains in brazilian children after immunization with an outer membrane vaccine. Infect Immun 1998, 66(10):4755-4761.
89. Martin D.R., Ruijne N., McCallum L., O'Hallahan J., Oster P. The VR2 epitope on the PorA P1. 7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13(4):486-491.
90. Oomen C.J., Hoogerhout P., Kuipers B., Vidarsson G., van Alphen L., Gros P. Crystal structure of an anti-meningococcal subtype P1. 4 porA antibody provides basis for peptide-vaccine design. J Mol Biol 2005, 351(5):1070-1080.
91. Humphries H.E., Williams J.N., Christodoulides M., Heckels J.E. Recombinant meningococcal PorA protein, expressed using a vector system with potential for human vaccination, induces a bactericidal immune response. Vaccine 2004, 22(11-12):1564-1569.
92. Arigita C., Kersten G.F., Hazendonk T., Hennink W.E., Crommelin D.J., Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine 2003, 21(9-10):950-960.
93. Christodoulides M., McGuinness B.T., Heckels J.E. Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide. J Gen Microbiol 1993, 139(8):1729-1738.
94. van der Ley P., Poolman J.T. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun 1992, 60(8):3156-3161.
95. Urwin R., Russell J.E., Thompson E.A., Holmes E.C., Feavers I.M., Maiden M.C. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004, 72(10):5955-5962.
96. van der Ley P., van der Biezen J., Poolman J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995, 13(4):401-407.
97. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996, 14(10):1001-1008.
98. Peeters C.C., Rümke H.C., Sundermann L.C., Rouppe van der Voort E.M., Meulenbelt J., Schuller M., et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996, 14(10):1009-1015.
99. de Kleijn E.D., de Groot R., Labadie J., Lafeber A.B., van den Dobbelsteen G., van Alphen L., et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane- vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000, 18(15):1456-1466.
100. van den Dobbelsteen G.P., van Dijken H., Hamstra H.J., Ummels R., van Alphen L., van der Ley P. From Hexamen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine. Proceedings of the 14th International Pathogenic Neisseria Conference 2004.
101. van den Dobbelsteen GP. NonaMen, a multivalent MenB OMV vaccine, from development to clinical trials. Vaccimonitor 18, 18. 2009.
102. Trotter C.L., Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007, 31(1):101-107.
103. Keiser P.B., Gibbs B.T., Coster T.S., Moran E.E., Stoddard M.B., Labrie J.E., et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 2010, 28(43):6970-6976.
104. Zollinger W.D., Donets M.A., Schmiel D.H., Pinto V.B., Labrie J.E., Moran E.E., et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 2010, 28(31):5057-5067.
105. Mascioni A., Bentley B.E., Camarda R., Dilts D.A., Fink P., Gusarova V., et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 2008, 284(13):8738-8746.
106. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(37):6086-6093.
107. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(29):10834-10839.
108. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
109. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
110. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176(12):7566-7575.
111. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(1):501-510.
112. Richmond P, Marshall H, Sheldon E, Jiang Q, Anderson A, Jansen K, et al. Safety & immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. 17th International Pathogenic Neisseria Conference: Programme and Abstract Guide, 37. 2010.
113. Richmond P, Marshall H, Nissen MD, Lambert S, Jones T, Gruber W, et al. A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. 16th International Pathogenic Neisseria Conference, Rotterdam, the Netherlands, 270. 2008.
114. Marshall H, Nissen MD, Richmond P, Lambert S., Robertson DM, Jones T, et al. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults. 16th International Pathogenic Neisseria Conference, Rotterdam, the Netherlands, 271. 2008.
115. Su E.L., Snape M.D. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines 2011, 10(5):575-588.
116. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29(7):1413-1420.
117. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24(24):5093-5107.
118. Michaelsen T.E., Garred P., Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991, 21(1):11-16.
119. Weynants V.E., Feron C.M., Goraj K.K., Bos M.P., Denoel P.A., Verlant V.G., et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007, 75(11):5434-5442.
120. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107(45):19490-19495.
121. McNeil LK, Zlotnick GW, Camposano E, Logan SM, Novikova E, Zhao XJ, et al. Development of a meningococcal antigen surface expression (MEASURE) assay for the phenotypic characterization of fhbp expression by Neisseria meningitidis. 11th EMGM Meeting.Ljubljana, Slovenija, 18-20 May 2011.
122. Claus H., Jordens M.S., Kriz P., Musilek M., Jarva H., Pawlik M.C., et al. Capsule null locus meningococci: Typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine. Vaccine 2012, 30(2):155-160.
123. Oriente F., Scarlato V., Delany I. Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J Bacteriol 2010, 192(3):691-701.
124. Perkins-Balding D., Ratliff-Griffin M., Stojiljkovic I. Iron transport systems in Neisseria meningitidis. Microbiol Mol Biol Rev 2004, 68(1):154-171.
125. Metruccio MME, Pigozzi E, Roncarati D, Berlanda Scorza F, Norais N, Hill SA, et al. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog. 2009;5(12): e1000710.